ZURICH (Reuters) – Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.
The Swiss drugmaker is developing and marketing the product under a license agreement with Genmab.
(Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)
